BioSpace

Ionis’ antisense drug stabilizes ultra-rare disease ahead of FDA decision

The pivotal study of zilganersen in Alexander disease missed a secondary endpoint, but analysts expect the FDA to approve the ...
STAT

FDA approves Ionis drug that prevents swelling attacks caused by a rare disease

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. Ionis Pharmaceuticals won approval from the Food and Drug Administration on ...
Yahoo

FDA approves Ionis’ hereditary angioedema drug

Add Yahoo as a preferred source to see more of our stories on Google. This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma ...
Seeking Alpha

Ionis announces zilganersen New Drug Application for Alexander disease (AxD) accepted by FDA for Priority Review

CARLSBAD, Calif.--(BUSINESS WIRE)-- Ionis Pharmaceuticals, Inc. (IONS) (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the New Drug ...
The Barre-Montpelier Times Argus

Ionis presents new data from pivotal study of zilganersen in Alexander disease (AxD) at AAN 2026 Annual Meeting

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced additional positive results from the pivotal study of zilganersen in children and adults living with Alexander disease (AxD), a rare, ...
Yahoo

US FDA approves Ionis' drug for rare genetic disorder

(Reuters) -The U.S. Food and Drug Administration on Thursday approved Ionis Pharmaceuticals' drug to prevent instances of severe swelling in various parts of the body of patients with a rare genetic ...
AOL

Ionis Pharma's Investigational Drug Shows Promise For Triglyceride And Pancreatitis Reduction

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) on Tuesday released topline results from the pivotal Phase 3 CORE and CORE2 studies of olezarsen for severe hypertriglyceridemia (sHTG). sHTG is a condition ...
Seeking Alpha

Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis

Development of BIIB105, an investigational antisense oligonucleotide for amyotrophic lateral sclerosis (ALS), will be discontinued based on data from the Phase 1/2 ALSpire study Biogen and Ionis ...
Fierce Pharma

Ionis exec shares method to the Madness after 2026 Drug Name Tournament win

Drug names are complicated things. For one, they must linguistically fulfill the role of being a shiny bauble for prescribers ...
Benzinga.com

GSK/Ionis Partnered Investigational Drug Shows Strong Results In Large Hepatitis B Studies

Ionis Pharmaceuticals Inc. (NASDAQ: IONS) partner GSK Plc (NYSE: GSK) on Wednesday shared data from two pivotal Phase 3 studies, B-Well 1 and B-Well 2, of bepirovirsen, an investigational antisense ...
AOL

Ionis' metabolic disorder drug lowers high levels of a type of fat in study

(Reuters) -Ionis Pharmaceuticals said on Tuesday its experimental drug met the main goal of reducing abnormally high levels of the most common type of body fat in a late-stage trial in patients with a ...